301075 多瑞医药
已收盘 10-09 15:00:00
资讯
新帖
简况
多瑞医药：公司多肽原料药产品主要有艾博韦泰、司美格鲁肽、替尔泊肽和兰瑞肽等
证券之星 · 10-09 16:06
多瑞医药：公司多肽原料药产品主要有艾博韦泰、司美格鲁肽、替尔泊肽和兰瑞肽等
多瑞医药（301075）披露向控股子公司提供担保进展公告，9月23日股价下跌1.61%
证券之星 · 09-23
多瑞医药（301075）披露向控股子公司提供担保进展公告，9月23日股价下跌1.61%
股市必读：多瑞医药新发布《北京大成律师事务所关于西藏多瑞医药股份有限公司2026年第二次临时股东会的法律意见书》
证券之星 · 09-14
股市必读：多瑞医药新发布《北京大成律师事务所关于西藏多瑞医药股份有限公司2026年第二次临时股东会的法律意见书》
多瑞医药（301075）披露向控股子公司提供担保的进展公告，9月10日股价下跌1.43%
证券之星 · 09-10
多瑞医药（301075）披露向控股子公司提供担保的进展公告，9月10日股价下跌1.43%
多瑞医药（301075）披露转让子公司及参股公司股权暨关联交易公告，9月4日股价下跌1.02%
证券之星 · 09-04
多瑞医药（301075）披露转让子公司及参股公司股权暨关联交易公告，9月4日股价下跌1.02%
多瑞医药（301075）2026年中报简析：净利润同比增长127.13%，存货明显上升
证券之星 · 08-27
多瑞医药（301075）2026年中报简析：净利润同比增长127.13%，存货明显上升
图解多瑞医药中报：第二季度单季净利润同比增长194.77%
证券之星 · 08-26
图解多瑞医药中报：第二季度单季净利润同比增长194.77%
多瑞医药（301075）股东曹晓兵质押240万股，占总股本3%
证券之星 · 06-30
多瑞医药（301075）股东曹晓兵质押240万股，占总股本3%
多瑞医药（301075）披露2025年年度股东会决议公告，5月22日股价上涨3.68%
证券之星 · 05-22
多瑞医药（301075）披露2025年年度股东会决议公告，5月22日股价上涨3.68%
多瑞医药（301075）披露关于变更股东会召开地点的公告，5月18日股价上涨0.1%
证券之星 · 05-18
多瑞医药（301075）披露关于变更股东会召开地点的公告，5月18日股价上涨0.1%
多瑞医药（301075）披露已回购股份减持结果暨股份变动公告，5月14日股价上涨5.97%
证券之星 · 05-14
多瑞医药（301075）披露已回购股份减持结果暨股份变动公告，5月14日股价上涨5.97%
股市必读：多瑞医药（301075）5月12日披露最新机构调研信息
证券之星 · 05-13
股市必读：多瑞医药（301075）5月12日披露最新机构调研信息
多瑞医药（301075）披露回购股份集中竞价减持进展公告，5月8日股价上涨4.21%
证券之星 · 05-08
多瑞医药（301075）披露回购股份集中竞价减持进展公告，5月8日股价上涨4.21%
每周股票复盘：多瑞医药（301075）股东户数增37.69%
证券之星 · 05-03
每周股票复盘：多瑞医药（301075）股东户数增37.69%
多瑞医药（301075）2026年一季报简析：亏损收窄，存货明显上升
证券之星 · 04-30
多瑞医药（301075）2026年一季报简析：亏损收窄，存货明显上升
图解多瑞医药一季报：第一季度单季净利润同比增长10.45%
证券之星 · 04-29
图解多瑞医药一季报：第一季度单季净利润同比增长10.45%
4月21日多瑞医药现1笔折价17.95%的大宗交易 合计成交528.51万元
证券之星 · 04-21
4月21日多瑞医药现1笔折价17.95%的大宗交易 合计成交528.51万元
多瑞医药：目前公司尚无该技术的应用
证券之星 · 04-21
多瑞医药：目前公司尚无该技术的应用
多瑞医药（301075）股东西藏嘉康时代科技发展有限公司质押160万股，占总股本2%
证券之星 · 2025-03-10
多瑞医药（301075）股东西藏嘉康时代科技发展有限公司质押160万股，占总股本2%
多瑞医药:公司如何保护投资者权益及展望未来发展
问董秘 · 2025-02-17
多瑞医药:公司如何保护投资者权益及展望未来发展
公司概况
公司名称：
西藏多瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-09-29
主营业务：
西藏多瑞医药股份有限公司的主营业务是药品制剂及化学中间体、多肽原料药的研发、生产和销售。公司的主要产品是原料药、中间体。
发行价格：
27.27
{"stockData":{"symbol":"301075","market":"SZ","secType":"STK","nameCN":"多瑞医药","latestPrice":59.95,"timestamp":1791529404000,"preClose":60.6,"halted":0,"volume":857700,"delay":0,"changeRate":-0.0107,"floatShares":56600000,"shares":80000000,"eps":-0.6018,"marketStatus":"已收盘","change":-0.65,"latestTime":"10-09 15:00:00","open":62.01,"high":62.01,"low":57.03,"amount":50427300,"amplitude":0.0822,"askPrice":59.96,"askSize":10,"bidPrice":59.94,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-0.6018,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":5,"adr":0,"adjPreClose":60.6,"symbolType":"stock","openAndCloseTimeList":[[1791509400000,1791516600000],[1791522000000,1791529200000]],"highLimit":66.66,"lowLimit":54.54,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":80000000,"isCdr":false,"pbRate":7.35,"roa":"--","roe":"1.9%","epsLYR":-1.29,"committee":0.738636,"marketValue":4796000000,"turnoverRate":0.0152,"status":1,"floatMarketCap":3393000000},"requestUrl":"/m/hq/s/301075/wiki","defaultTab":"wiki","newsList":[{"id":"2674834969","title":"多瑞医药：公司多肽原料药产品主要有艾博韦泰、司美格鲁肽、替尔泊肽和兰瑞肽等","url":"https://stock-news.laohu8.com/highlight/detail?id=2674834969","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674834969?lang=zh_cn&edition=full","pubTime":"2026-10-09 16:06","pubTimestamp":1791533167,"startTime":"0","endTime":"0","summary":"证券之星消息，多瑞医药10月08日在投资者关系平台上答复投资者关心的问题。据透露GLP-1 年产能达3000Kg，请问目前多瑞医药的多肽原料药在国内外的对标公司有哪些。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900022897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669844504","title":"多瑞医药（301075）披露向控股子公司提供担保进展公告，9月23日股价下跌1.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669844504","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669844504?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:32","pubTimestamp":1790173938,"startTime":"0","endTime":"0","summary":"截至2026年9月23日收盘，多瑞医药报收于66.18元，较前一交易日下跌1.61%，最新总市值为52.94亿元。多瑞医药于近日披露《关于向控股子公司提供担保的进展公告》。公告显示，公司于2025年10月审议通过为控股子公司湖北鑫承达化工有限公司增加不超过3,000万元人民币的连带责任保证担保额度。保证期间均为债务履行期限届满之日起三年。截至公告日，公司实际对外担保余额为2,000万元，占最近一期经审计净资产的3.21%，无对合并报表外单位的担保，无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300041297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667638800","title":"股市必读：多瑞医药新发布《北京大成律师事务所关于西藏多瑞医药股份有限公司2026年第二次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667638800","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667638800?lang=zh_cn&edition=full","pubTime":"2026-09-14 03:02","pubTimestamp":1789326138,"startTime":"0","endTime":"0","summary":"公司公告汇总：2026年第二次临时股东会审议通过《关于转让子公司股权暨关联交易的议案》，同意率99.8875%，中小投资者同意率为47.7271%。2026年第二次临时股东会决议公告西藏多瑞医药股份有限公司于2026年9月11日召开2026年第二次临时股东会，会议由董事会召集，王庆太主持，采用现场与网络投票结合方式召开。北京大成律师事务所出具法律意见书，认为本次股东会召集召开程序、出席会议人员资格、表决程序及结果合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400001204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666384562","title":"多瑞医药（301075）披露向控股子公司提供担保的进展公告，9月10日股价下跌1.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666384562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666384562?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:04","pubTimestamp":1789034663,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，多瑞医药报收于58.39元，较前一交易日下跌1.43%，最新总市值为46.71亿元。该股当日开盘59.23元，最高59.24元，最低57.3元，成交额达3414.01万元，换手率为1.04%。近日，西藏多瑞医药股份有限公司发布公告，公司与成都农商银行金堂竹篙支行签署《保证合同》，为控股子公司四川多瑞药业有限公司申请的1,000万元综合授信额度提供连带责任保证担保，担保期限为主合同项下债务履行期限届满之日起三年。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000033377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664333060","title":"多瑞医药（301075）披露转让子公司及参股公司股权暨关联交易公告，9月4日股价下跌1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333060","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664333060?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:41","pubTimestamp":1788514895,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，多瑞医药报收于61.14元，较前一交易日下跌1.02%，最新总市值为48.91亿元。近日，多瑞医药披露《关于转让子公司及参股公司股权暨关联交易的公告》。西藏嘉康为公司持股5%以上股东，本次交易构成关联交易。本次关联交易已经董事会审议通过，无需提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400031724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662728460","title":"多瑞医药（301075）2026年中报简析：净利润同比增长127.13%，存货明显上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2662728460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662728460?lang=zh_cn&edition=full","pubTime":"2026-08-27 06:49","pubTimestamp":1787784546,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期多瑞医药发布2026年中报。截至本报告期末，公司营业总收入9565.54万元，同比下降10.24%，归母净利润1152.94万元，同比上升127.13%。按单季度数据看，第二季度营业总收入6322.42万元，同比上升10.67%，第二季度归母净利润2549.74万元，同比上升194.77%。本报告期多瑞医药存货明显上升，存货同比增幅达119.17%。本次财报公布的各项数据指标表现一般。），公司上市来已有年报5份，亏损年份2次，显示生意模式比较脆弱。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700013516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662754816","title":"图解多瑞医药中报：第二季度单季净利润同比增长194.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662754816","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662754816?lang=zh_cn&edition=full","pubTime":"2026-08-26 03:33","pubTimestamp":1787686412,"startTime":"0","endTime":"0","summary":"证券之星消息，多瑞医药2026年中报显示，上半年度公司主营收入9565.54万元，同比下降10.24%；归母净利润1152.94万元，同比上升127.13%；扣非净利润-3343.76万元，同比上升26.54%；其中2026年第二季度，公司单季度主营收入6322.42万元，同比上升10.67%；单季度归母净利润2549.74万元，同比上升194.77%；单季度扣非净利润-1899.06万元，同比上升33.39%；负债率46.58%，投资收益4020.53万元，财务费用664.43万元，毛利率11.2%。财报数据概要请见下图:本文数据来源于多瑞医药2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600005678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647537900","title":"多瑞医药（301075）股东曹晓兵质押240万股，占总股本3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647537900","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647537900?lang=zh_cn&edition=full","pubTime":"2026-06-30 18:33","pubTimestamp":1782815604,"startTime":"0","endTime":"0","summary":"证券之星消息，多瑞医药6月30日公开信息显示，股东曹晓兵向秦皇岛银行股份有限公司远洋支行合计质押240.0万股，占总股本3.0%。质押详情见下表：截止本公告日，股东曹晓兵已累计质押股份240.0万股，占其持股总数的25.0%。多瑞医药主营业务：化学药品制剂及其原料药的研发、生产和销售。本文数据来源于多瑞医药公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000037429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637907383","title":"多瑞医药（301075）披露2025年年度股东会决议公告，5月22日股价上涨3.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637907383","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637907383?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:36","pubTimestamp":1779442592,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，多瑞医药报收于88.2元，较前一交易日上涨3.68%，最新总市值为70.56亿元。该股当日开盘85.95元，最高88.88元，最低83.0元，成交额达1.83亿元，换手率为2.68%。近日，多瑞医药披露《2025年年度股东会决议公告》。公告显示，公司于2026年5月21日召开2025年年度股东会，会议由董事会召集，董事长王庆太主持，采用现场与网络投票相结合方式召开。出席会议股东及代理人共30人，代表股份52,728,901股，占公司有效表决权总股份的65.9111%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200033027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636021757","title":"多瑞医药（301075）披露关于变更股东会召开地点的公告，5月18日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636021757","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636021757?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:50","pubTimestamp":1779097845,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，多瑞医药报收于83.79元，较前一交易日上涨0.1%，最新总市值为67.03亿元。该股当日开盘83.54元，最高86.42元，最低81.0元，成交额达1.93亿元，换手率为2.86%。近日，多瑞医药发布《关于变更股东会召开地点的公告》。会议时间、股权登记日、会议提案等内容均保持不变。现场会议时间为2026年5月21日10:00，股权登记日为2026年5月15日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800028346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635745977","title":"多瑞医药（301075）披露已回购股份减持结果暨股份变动公告，5月14日股价上涨5.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635745977","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635745977?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:22","pubTimestamp":1778768536,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，多瑞医药报收于87.2元，较前一交易日上涨5.97%，最新总市值为69.76亿元。近日，西藏多瑞医药股份有限公司发布《关于已回购股份减持结果暨股份变动公告》。公告显示，公司于2025年12月19日审议通过减持已回购股份计划，拟通过集中竞价方式减持不超过1,044,500股，占总股本1.31%。减持期间为2026年1月14日至2026年7月13日。减持后回购专用账户持股为0。本次减持不影响公司控制权，所得资金用于补充流动资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400042981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635824904","title":"股市必读：多瑞医药（301075）5月12日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2635824904","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635824904?lang=zh_cn&edition=full","pubTime":"2026-05-13 01:32","pubTimestamp":1778607130,"startTime":"0","endTime":"0","summary":"截至2026年5月12日收盘，多瑞医药报收于80.39元，下跌4.43%，换手率5.41%，成交量4.33万手，成交额3.55亿元。2025年公司研发投入共计3,241.09万元，占营业收入比例达到21.02%，全部为费用化投入，未进行资本化处理，研发投入占比提升主要因营业收入下降所致。公司于2025年12月5日正式完成控股股东及实际控制人变更，原实际控制人为邓勇，变更后由王庆太、崔子浩、曹晓兵三人成为新的实际控制人，三人互为一致行动人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300001739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633390644","title":"多瑞医药（301075）披露回购股份集中竞价减持进展公告，5月8日股价上涨4.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633390644","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633390644?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:33","pubTimestamp":1778232808,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，多瑞医药报收于84.93元，较前一交易日上涨4.21%，最新总市值为67.94亿元。近日，西藏多瑞医药股份有限公司披露《关于回购股份集中竞价减持的进展公告》。公告显示，公司于2025年12月19日审议通过《关于回购股份集中竞价减持计划的议案》，拟通过集中竞价方式减持已回购股份，数量不超过1,044,500股，占总股本1.31%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800031415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632467771","title":"每周股票复盘：多瑞医药（301075）股东户数增37.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632467771","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632467771?lang=zh_cn&edition=full","pubTime":"2026-05-03 06:10","pubTimestamp":1777759824,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，多瑞医药报收于83.45元，较上周的79.16元上涨5.42%。股本股东变化股东户数变动截至2026年3月31日，多瑞医药股东户数为6865.0户，较12月31日增加1879.0户，增幅37.69%。公司公告汇总2026年一季度报告西藏多瑞医药股份有限公司2026年第一季度报告显示，报告期内营业收入为32,431,205.53元，较上年同期下降34.41%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631785765","title":"多瑞医药（301075）2026年一季报简析：亏损收窄，存货明显上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2631785765","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631785765?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:48","pubTimestamp":1777502927,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期多瑞医药发布2026年一季报。本报告期多瑞医药存货明显上升，存货同比增幅达69.16%。其中，毛利率7.54%，同比减54.92%，净利率-58.63%，同比减27.61%，销售费用、管理费用、财务费用总计1843.6万元，三费占营收比56.85%，同比增7.08%，每股净资产7.71元，同比减6.67%，每股经营性现金流-0.46元，同比减128.64%，每股收益-0.18元，同比增10.0%证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-85.88%，算上全部成本后，公司产品或服务的附加值不高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000023308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631539125","title":"图解多瑞医药一季报：第一季度单季净利润同比增长10.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631539125","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631539125?lang=zh_cn&edition=full","pubTime":"2026-04-29 04:54","pubTimestamp":1777409652,"startTime":"0","endTime":"0","summary":"证券之星消息，多瑞医药2026年一季报显示，一季度公司主营收入3243.12万元，同比下降34.41%；归母净利润-1396.8万元，同比上升10.45%；扣非净利润-1444.7万元，同比上升15.06%；负债率50.21%，投资收益-26.39万元，财务费用335.11万元，毛利率7.54%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900010696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629983081","title":"4月21日多瑞医药现1笔折价17.95%的大宗交易 合计成交528.51万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629983081","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2629983081?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:08","pubTimestamp":1776762519,"startTime":"0","endTime":"0","summary":"证券之星消息，4月21日多瑞医药发生大宗交易，交易数据如下：大宗交易成交价格66.9元，相对当日收盘价折价17.95%，成交7.9万股，成交金额528.51万元，买方营业部为招商证券股份有限公司上海牡丹江路证券营业部，卖方营业部为国联民生证券股份有限公司北京分公司。近三个月该股共发生5笔大宗交易，合计成交6690.0手，折价成交5笔。截至2026年4月21日收盘，多瑞医药报收于81.54元，下跌0.07%，换手率3.56%，成交量2.85万手，成交额2.32亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100038307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629770172","title":"多瑞医药：目前公司尚无该技术的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2629770172","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2629770172?lang=zh_cn&edition=full","pubTime":"2026-04-21 08:51","pubTimestamp":1776732686,"startTime":"0","endTime":"0","summary":"证券之星消息，多瑞医药(301075)04月20日在投资者关系平台上答复投资者关心的问题。投资者提问：目前行业内在仲丁基锂连续流规模化生产上已出现明显技术领先企业，该技术直接决定高难度创新药分子的可开发性与商业化效率。请问公司是否掌握相关核心工艺？有无具体项目案例、产能规模及客户验证？若存在明显技术代差，将如何应对高端订单流失的风险？多瑞医药回复：尊敬的投资者您好，目前公司尚无该技术的应用。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100014164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518220054","title":"多瑞医药（301075）股东西藏嘉康时代科技发展有限公司质押160万股，占总股本2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220054","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518220054?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:15","pubTimestamp":1741616141,"startTime":"0","endTime":"0","summary":"证券之星消息，多瑞医药3月10日公开信息显示，股东西藏嘉康时代科技发展有限公司向李阳合计质押160.0万股，占总股本2.0%。质押详情见下表：截止本公告日，股东西藏嘉康时代科技发展有限公司已累计质押股份2082.44万股，占其持股总数的44.61%。多瑞医药主营业务：化学药品制剂及其原料药的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000033409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512961800","title":"多瑞医药:公司如何保护投资者权益及展望未来发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2512961800","media":"问董秘","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512961800?lang=zh_cn&edition=full","pubTime":"2025-02-17 08:51","pubTimestamp":1739753460,"startTime":"0","endTime":"0","summary":"投资者提问：2024年末致电贵公司证券部，询问平价入股鑫承达和四川多瑞，没有作相关对赌，由于平价进行，公司在二次并购中均不构成重组事项，只是以自有资金购买资产，而且证券代表均表示资产价格较低，有利于公司发展。鑫承达及四川多瑞的生产经营正有序进行，公司会加快推进中间体和高端多肽原料药项目的研发、生产和商业化，实现新的业绩和利润增长点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/dongmiqa/2025-02-17/doc-inektywk3534976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","301075"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791636341972,"stockEarnings":[{"period":"1week","weight":-0.051},{"period":"1month","weight":0.012},{"period":"3month","weight":-0.0544},{"period":"6month","weight":-0.0879},{"period":"1year","weight":0.4958},{"period":"ytd","weight":0.0047}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0349},{"period":"3month","weight":-0.0456},{"period":"6month","weight":-0.0433},{"period":"1year","weight":-0.0305},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"西藏多瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6628人(较上一季度减少3.45%)","perCapita":"8539股","listingDate":"2021-09-29","address":"西藏自治区昌都市卡若区经济技术开发区A区创业大道9号","registeredCapital":"8000万元","survey":" 西藏多瑞医药股份有限公司的主营业务是药品制剂及化学中间体、多肽原料药的研发、生产和销售。公司的主要产品是原料药、中间体。","listedPrice":27.27},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"多瑞医药(301075)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供多瑞医药(301075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"多瑞医药,301075,多瑞医药股票,多瑞医药股票老虎,多瑞医药股票老虎国际,多瑞医药行情,多瑞医药股票行情,多瑞医药股价,多瑞医药股市,多瑞医药股票价格,多瑞医药股票交易,多瑞医药股票购买,多瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"多瑞医药(301075)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供多瑞医药(301075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}